<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623816</url>
  </required_header>
  <id_info>
    <org_study_id>13-00089</org_study_id>
    <nct_id>NCT02623816</nct_id>
  </id_info>
  <brief_title>Prospective Study Assessing Patient Satisfaction of Symptom Control With Proton Pump Inhibitor Dosing Regimen</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetroHealth Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MetroHealth Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this study is to assess if patients with persistent GERD symptoms
      receiving sub-optimal omeprazole dosing experience improvement in GERD symptoms when
      prescribed an optimal dosing regimen. The optimal dosing regimen is defined as taking
      omeprazole 30 minutes prior to the first meal of the day.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom frequency and severity/distress scores from GSAS (overall)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom frequency and severity/distress scores from GSAS (overall)</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom frequency and severity/distress scores from GSAS (Gastrointestinal distress)</measure>
    <time_frame>6 weeks, 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom frequency and severity/distress scores from GSAS (Heartburn)</measure>
    <time_frame>6 weeks, 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom frequency and severity/distress scores from GSAS (Upper respiratory symptoms)</measure>
    <time_frame>6 weeks, 10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Heartburn</condition>
  <arm_group>
    <arm_group_label>Sub-optimal/optimal dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will not change sub-optimal dosing regimen of omeprazole 20 mg for 6 weeks after which they will receive optimal dosing of omeprazole for 4 weeks. Rescue antacid use is permitted. Total duration of 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-optimal dosing</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No change will be made to the sub-optimal dosing regimen of omeprazole 20 mg. Rescue antacid use is permitted. Total duration of 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be administered optimal dosing of Omeprazole 20 mg for 4 weeks starting at week 2. Rescue antacid use is permitted. Total duration of 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimal Dosing of Omeprazole</intervention_name>
    <description>Omeprazole 20 mg</description>
    <arm_group_label>Sub-optimal/optimal dosing</arm_group_label>
    <arm_group_label>Optimal dosing</arm_group_label>
    <other_name>omeprazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥ 18 years old

          -  taking omeprazole 20 mg

          -  episodic heartburn at least 3 times per week

          -  provides consent and be willing to complete study questionnaires

          -  read, speak and write English

        Exclusion Criteria:

          -  weight loss (alarm symptom)

          -  normal esophagogastroduodenoscopy (EGD) in last one year

          -  pregnant or women planning on becoming pregnant at any time during the study

          -  history of Barrett's esophagus

          -  prior esophageal strictures

          -  intolerance/allergy to study medications

          -  patients on plavix or a history of upper gastrointestinal surgery

          -  investigators or their immediate family (spouse, children, sibling)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Michael Wolfe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MetroHealth Medical System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abhijeet Waghray, MD</last_name>
    <phone>216-778-3347</phone>
    <email>awaghray@metrohealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nisheet Waghray, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MetroHealth Medical System</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abhijeet Waghray, MD</last_name>
      <phone>216-778-3347</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>December 3, 2015</last_update_submitted>
  <last_update_submitted_qc>December 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MetroHealth Medical Center</investigator_affiliation>
    <investigator_full_name>M. Michael Wolfe</investigator_full_name>
    <investigator_title>Chairman of Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

